NCT04258007View on ClinicalTrials.gov

Sugammadex Versus Neostigmine in Pediatric Less Than Two Years Undergoing Cardiac Catheterization

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 27, 2020

Primary Completion Date

November 10, 2020

Study Completion Date

November 18, 2020

Conditions
Cardiac Catheterization
Interventions
DRUG

Reversal Neostigmine

Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch

DRUG

Reversal Sugammadex

Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch

Trial Locations (1)

050

Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04258007 - Sugammadex Versus Neostigmine in Pediatric Less Than Two Years Undergoing Cardiac Catheterization | Biotech Hunter | Biotech Hunter